VAS: People vaccinated against COVID-19 are unlikely to have an increased risk of blood clots



[ad_1]

“Currently, available information suggests that the number of thromboembolic events among vaccinated people is not higher than in the general population,” the European Medicines Agency (EMA) wrote in a letter to the news agency requesting comment on the decisions of countries to stop vaccination.

The Amsterdam-based agency said it believed the Danish decision “was taken as a precautionary measure.”

The EEA added that the decision followed an announcement by the agency itself on Wednesday that it was “investigating cases of thromboembolism that were reported to be related to the vaccine over time.”

Austria announced on Monday that it would discontinue vaccines with a batch of AstraZeneca vaccines after a 49-year-old nurse had a “significant increase in blood clotting” a few days after injecting COVID-19.

Four other EU countries – Estonia, Latvia, Lithuania and Luxembourg – have also announced the cessation of vaccination with this batch, which produced a total of 1 million. doses distributed in 17 European countries.

At the time, Denmark announced that it was suspending vaccination with all available AstraZeneca stocks, followed by Iceland and Norway.

The European Medicines Agency has stated that it “will continue its evaluation … and will continue to publish updates as soon as possible”.

In its report on the incident in Austria, the EEA stated that, as of March 9, 22 cases of blood clots had been reported in the European Economic Area (EEA).

Denmark will re-evaluate the decision to suspend vaccination after two weeks. This measure is likely to slow down the vaccination campaign in the country.

Copenhagen currently expects all adults in the country to be vaccinated by mid-August, the health board said. It was previously predicted that this would be done in early July.



[ad_2]